請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71249
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 詹迺立(Nei-Li Chan) | |
dc.contributor.author | Chao-Ming Hsieh | en |
dc.contributor.author | 謝詔名 | zh_TW |
dc.date.accessioned | 2021-06-17T05:00:55Z | - |
dc.date.available | 2020-08-27 | |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-19 | |
dc.identifier.citation | 1. S. H. Francis, M. A. Blount, J. D. Corbin, Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91, 651-690 (2011). 2. M. F. Azevedo, F. R. Faucz, E. Bimpaki, A. Horvath, I. Levy, R. B. de Alexandre, F. Ahmad, V. Manganiello, C. A. Stratakis, Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 35, 195-233 (2014). 3. M. Conti, J. Beavo, Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76, 481-511 (2007). 4. D. H. Maurice, H. Ke, F. Ahmad, Y. Wang, J. Chung, V. C. Manganiello, Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13, 290-314 (2014). 5. G. S. Baillie, G. S. Tejeda, M. P. Kelly, Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov 18, 770-796 (2019). 6. M. P. DeNinno, Future directions in phosphodiesterase drug discovery. Bioorg Med Chem Lett 22, 6794-6800 (2012). 7. A. T. Bender, J. A. Beavo, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58, 488-520 (2006). 8. J. D. Corbin, Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 Suppl 1, S4-7 (2004). 9. M. S. Miller, Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential. J Recept Ligand Ch R 8, 19-30 (2015). 10. K. Arakawa, S. Maehara, Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats. Neuropsychopharmacol Rep, (2020). 11. E. Zuccarello, E. Acquarone, E. Calcagno, E. K. Argyrousi, S. X. Deng, D. W. Landry, O. Arancio, J. Fiorito, Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. Biochem Pharmacol 176, 113818 (2020). 12. V. Leukes, G. Walzl, N. du Plessis, Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis. Front Immunol 11, 451 (2020). 13. M. S. Bugday, E. Oksuz, A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors. Med Hypotheses 141, 109694 (2020). 14. X. F. Huang, Y. H. Dong, J. H. Wang, H. M. Ke, G. Q. Song, D. F. Xu, Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 30, 127097 (2020). 15. Y. Chen, S. Li, X. Zhong, Z. Kang, R. Chen, PDE-7 Inhibitor BRL-50481 Reduces Neurodegeneration and Long-Term Memory Deficits in Mice Following Sevoflurane Exposure. ACS Chem Neurosci 11, 1353-1358 (2020). 16. J. F. Chang, J. L. Hsu, Y. H. Sheng, W. J. Leu, C. C. Yu, S. H. Chan, M. L. Chan, L. C. Hsu, S. P. Liu, J. H. Guh, Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems. Front Oncol 8, 681 (2018). 17. B. N. Islam, S. K. Sharman, Y. Hou, A. E. Bridges, N. Singh, S. Kim, R. Kolhe, J. Trillo-Tinoco, P. C. Rodriguez, F. G. Berger, S. Sridhar, D. D. Browning, Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. Cancer Prev Res (Phila) 10, 377-388 (2017). 18. M. Packer, J. R. Carver, R. J. Rodeheffer, R. J. Ivanhoe, R. DiBianco, S. M. Zeldis, G. H. Hendrix, W. J. Bommer, U. Elkayam, M. L. Kukin, et al., Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325, 1468-1475 (1991). 19. L. M. Fabbri, P. M. Calverley, J. L. Izquierdo-Alonso, D. S. Bundschuh, M. Brose, F. J. Martinez, K. F. Rabe, M, M. s. groups, Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374, 695-703 (2009). 20. A. Morales, C. Gingell, M. Collins, P. A. Wicker, I. H. Osterloh, Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 10, 69-73; discussion 73-64 (1998). 21. W. J. Hellstrom, M. Gittelman, G. Karlin, T. Segerson, M. Thibonnier, T. Taylor, H. Padma-Nathan, Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23, 763-771 (2002). 22. H. Padma-Nathan, J. G. McMurray, W. E. Pullman, J. S. Whitaker, J. B. Saoud, K. M. Ferguson, R. C. Rosen, I. C. O.-D. D. S. Group, On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13, 2-9 (2001). 23. T. Sakamoto, Y. Koga, M. Hikota, K. Matsuki, M. Murakami, K. Kikkawa, K. Fujishige, J. Kotera, K. Omori, H. Morimoto, K. Yamada, The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor. Bioorg Med Chem Lett 24, 5460-5465 (2014). 24. G. T. Kedia, S. Uckert, F. Assadi-Pour, M. A. Kuczyk, K. Albrecht, Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Ther Adv Urol 5, 35-41 (2013). 25. M. C. Ford, P. S. Ho, Computational Tools To Model Halogen Bonds in Medicinal Chemistry. J Med Chem 59, 1655-1670 (2016). 26. R. Wilcken, M. O. Zimmermann, A. Lange, S. Zahn, F. M. Boeckler, Using halogen bonds to address the protein backbone: a systematic evaluation. J Comput Aided Mol Des 26, 935-945 (2012). 27. B. J. Sung, K. Y. Hwang, Y. H. Jeon, J. I. Lee, Y. S. Heo, J. H. Kim, J. Moon, J. M. Yoon, Y. L. Hyun, E. Kim, S. J. Eum, S. Y. Park, J. O. Lee, T. G. Lee, S. Ro, J. M. Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425, 98-102 (2003). 28. K. Y. Zhang, G. L. Card, Y. Suzuki, D. R. Artis, D. Fong, S. Gillette, D. Hsieh, J. Neiman, B. L. West, C. Zhang, M. V. Milburn, S. H. Kim, J. Schlessinger, G. Bollag, A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15, 279-286 (2004). 29. G. L. Card, B. P. England, Y. Suzuki, D. Fong, B. Powell, B. Lee, C. Luu, M. Tabrizizad, S. Gillette, P. N. Ibrahim, D. R. Artis, G. Bollag, M. V. Milburn, S. H. Kim, J. Schlessinger, K. Y. Zhang, Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12, 2233-2247 (2004). 30. H. Wang, Y. Liu, Q. Huai, J. Cai, R. Zoraghi, S. H. Francis, J. D. Corbin, H. Robinson, Z. Xin, G. Lin, H. Ke, Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281, 21469-21479 (2006). 31. H. Wang, M. Ye, H. Robinson, S. H. Francis, H. Ke, Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol 73, 104-110 (2008). 32. D. Liebschner, P. V. Afonine, M. L. Baker, G. Bunkoczi, V. B. Chen, T. I. Croll, B. Hintze, L. W. Hung, S. Jain, A. J. McCoy, N. W. Moriarty, R. D. Oeffner, B. K. Poon, M. G. Prisant, R. J. Read, J. S. Richardson, D. C. Richardson, M. D. Sammito, O. V. Sobolev, D. H. Stockwell, T. C. Terwilliger, A. G. Urzhumtsev, L. L. Videau, C. J. Williams, P. D. Adams, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol 75, 861-877 (2019). 33. P. V. Afonine, R. W. Grosse-Kunstleve, A. Urzhumtsev, P. D. Adams, Automatic multiple-zone rigid-body refinement with a large convergence radius. J Appl Crystallogr 42, 607-615 (2009). 34. P. V. Afonine, R. W. Grosse-Kunstleve, P. D. Adams, A. Urzhumtsev, Bulk-solvent and overall scaling revisited: faster calculations, improved results. Acta Crystallogr D Biol Crystallogr 69, 625-634 (2013). 35. P. V. Afonine, R. W. Grosse-Kunstleve, N. Echols, J. J. Headd, N. W. Moriarty, M. Mustyakimov, T. C. Terwilliger, A. Urzhumtsev, P. H. Zwart, P. D. Adams, Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 68, 352-367 (2012). 36. J. J. Headd, N. Echols, P. V. Afonine, R. W. Grosse-Kunstleve, V. B. Chen, N. W. Moriarty, D. C. Richardson, J. S. Richardson, P. D. Adams, Use of knowledge-based restraints in phenix.refine to improve macromolecular refinement at low resolution. Acta Crystallogr D Biol Crystallogr 68, 381-390 (2012). 37. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010). 38. J. M. Humphrey, E. Yang, C. W. A. Ende, E. P. Arnold, J. L. Head, S. Jenkinson, L. A. Lebel, S. Liras, J. Pandit, B. Samas, F. Vajdos, S. P. Simons, A. Evdokimov, M. Mansour, F. S. Menniti, Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1. Medchemcomm 5, 1290-1296 (2014). 39. J. Zhu, Q. Yang, D. Dai, Q. Huang, X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. J Am Chem Soc 135, 11708-11711 (2013). 40. G. Scapin, S. B. Patel, C. Chung, J. P. Varnerin, S. D. Edmondson, A. Mastracchio, E. R. Parmee, S. B. Singh, J. W. Becker, L. H. Van der Ploeg, M. R. Tota, Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43, 6091-6100 (2004). 41. L. Carzaniga, G. Amari, A. Rizzi, C. Capaldi, R. De Fanti, E. Ghidini, G. Villetti, C. Carnini, N. Moretto, F. Facchinetti, P. Caruso, G. Marchini, L. Battipaglia, R. Patacchini, V. Cenacchi, R. Volta, F. Amadei, A. Pappani, S. Capacchi, V. Bagnacani, M. Delcanale, P. Puccini, S. Catinella, M. Civelli, E. Armani, Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases. J Med Chem 60, 10026-10046 (2017). 42. S. Gulati, K. Palczewski, A. Engel, H. Stahlberg, L. Kovacik, Cryo-EM structure of phosphodiesterase 6 reveals insights into the allosteric regulation of type I phosphodiesterases. Sci Adv 5, eaav4322 (2019). 43. K. Kawai, Y. Endo, T. Asano, S. Amano, K. Sawada, N. Ueo, N. Takahashi, Y. Sonoda, M. Nagai, N. Kamei, N. Nagata, Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a new series of potent phosphodiesterase 7 inhibitors. J Med Chem 57, 9844-9854 (2014). 44. H. Wang, Z. Yan, S. Yang, J. Cai, H. Robinson, H. Ke, Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47, 12760-12768 (2008). 45. H. Wang, X. Luo, M. Ye, J. Hou, H. Robinson, H. Ke, Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis. J Med Chem 53, 1726-1731 (2010). 46. W. D. Shipe, S. S. Sharik, J. C. Barrow, G. B. McGaughey, C. R. Theberge, J. M. Uslaner, Y. Yan, J. J. Renger, S. M. Smith, P. J. Coleman, C. D. Cox, Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. J Med Chem 58, 7888-7894 (2015). 47. E. Krieger, K. Joo, J. Lee, J. Lee, S. Raman, J. Thompson, M. Tyka, D. Baker, K. Karplus, Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins 77 Suppl 9, 114-122 (2009). 48. N. Guex, M. C. Peitsch, T. Schwede, Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30 Suppl 1, S162-173 (2009). 49. M. Bertoni, F. Kiefer, M. Biasini, L. Bordoli, T. Schwede, Modeling protein quaternary structure of homo- and hetero-oligomers beyond binary interactions by homology. Sci Rep 7, 10480 (2017). 50. G. Studer, C. Rempfer, A. M. Waterhouse, R. Gumienny, J. Haas, T. Schwede, QMEANDisCo-distance constraints applied on model quality estimation. Bioinformatics 36, 1765-1771 (2020). 51. S. Bienert, A. Waterhouse, T. A. de Beer, G. Tauriello, G. Studer, L. Bordoli, T. Schwede, The SWISS-MODEL Repository-new features and functionality. Nucleic Acids Res 45, D313-D319 (2017). 52. A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F. T. Heer, T. A. P. de Beer, C. Rempfer, L. Bordoli, R. Lepore, T. Schwede, SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46, W296-W303 (2018). 53. R. A. Laskowski, M. B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51, 2778-2786 (2011). 54. Schrodinger, LLC. (2015). 55. B. Martin, C. J. Pallen, J. H. Wang, D. J. Graves, Use of fluorinated tyrosine phosphates to probe the substrate specificity of the low molecular weight phosphatase activity of calcineurin. J Biol Chem 260, 14932-14937 (1985). 56. C. M. Hsieh, C. Y. Chen, J. W. Chern, N. L. Chan, Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guide-lines for Targeting alpha-Helix Backbone Oxygen by Halogen Bonding. J Med Chem, (2020). 57. T. L. Fink, S. H. Francis, A. Beasley, K. A. Grimes, J. D. Corbin, Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 274, 34613-34620 (1999). 58. N. N. Shang, Y. X. Shao, Y. H. Cai, M. Guan, M. Huang, W. Cui, L. He, Y. J. Yu, L. Huang, Z. Li, X. Z. Bu, H. Ke, H. B. Luo, Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochem Pharmacol 89, 86-98 (2014). 59. L. C. Gilday, S. W. Robinson, T. A. Barendt, M. J. Langton, B. R. Mullaney, P. D. Beer, Halogen Bonding in Supramolecular Chemistry. Chem Rev 115, 7118-7195 (2015). 60. E. Persch, O. Dumele, F. Diederich, Molecular recognition in chemical and biological systems. Angew Chem Int Ed Engl 54, 3290-3327 (2015). 61. G. Cavallo, P. Metrangolo, R. Milani, T. Pilati, A. Priimagi, G. Resnati, G. Terraneo, The Halogen Bond. Chem Rev 116, 2478-2601 (2016). 62. M. Carter, P. S. Ho, Assaying the Energies of Biological Halogen Bonds. Cryst Growth Des 11, 5087-5095 (2011). 63. A. R. Voth, F. A. Hays, P. S. Ho, Directing macromolecular conformation through halogen bonds. Proc Natl Acad Sci U S A 104, 6188-6193 (2007). 64. P. Politzer, J. S. Murray, T. Clark, Halogen bonding: an electrostatically-driven highly directional noncovalent interaction. Phys Chem Chem Phys 12, 7748-7757 (2010). 65. L. Mendez, G. Henriquez, S. Sirimulla, M. Narayan, Looking Back, Looking Forward at Halogen Bonding in Drug Discovery. Molecules 22, (2017). 66. S. Sirimulla, J. B. Bailey, R. Vegesna, M. Narayan, Halogen interactions in protein-ligand complexes: implications of halogen bonding for rational drug design. J Chem Inf Model 53, 2781-2791 (2013). 67. X. Li, O. Keskin, B. Ma, R. Nussinov, J. Liang, Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. J Mol Biol 344, 781-795 (2004). 68. G. Mugumbate, V. Mendes, M. Blaszczyk, M. Sabbah, G. Papadatos, J. Lelievre, L. Ballell, D. Barros, C. Abell, T. L. Blundell, J. P. Overington, Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach. Front Pharmacol 8, 681 (2017). 69. J. L. Zurawin, C. A. Stewart, J. E. Anaissie, F. A. Yafi, W. J. Hellstrom, Avanafil for the treatment of erectile dysfunction. Expert Rev Clin Pharmacol 9, 1163-1170 (2016). 70. R. Wang, A. L. Burnett, W. H. Heller, K. Omori, J. Kotera, K. Kikkawa, S. Yee, W. W. Day, K. DiDonato, C. A. Peterson, Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 9, 2122-2129 (2012). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71249 | - |
dc.description.abstract | 3',5'-環核苷酸磷酸二酯酶酵素家族包含11種亞型,其成員負責調控細胞內cAMP及cGMP兩種3',5'-環核苷酸的降解。cAMP及cGMP為細胞內非常重要的第二傳訊者,可活化多種訊息傳遞途徑,進而影響細胞增值、分化、存活、細胞凋亡等生理作用,可知3',5'-環核苷酸磷酸二酯酶的活性對於細胞的運作非常重要,也因此3',5'-環核苷酸磷酸二酯酶是很好的藥物設計標的。藉著抑制其催化活性,可以調節細胞的功能進而達到緩解相關疾病的目的。在已開發完成的各類亞型抑制藥物中,第五型磷酸二酯酶的專一性抑制藥物是最成功的案例之一。目前已於臨床上使用的西地那非 (sildenafil)、伐地那非 (vardenafil)、他達拉非 (tadalafil)及阿伐那非 (avanafil)皆已廣泛的用來治療肺動脈高壓,心血管疾病,前列腺增生和男性性功能障礙等疾病。在這些抑制劑中,阿伐那非為唯一的第二代藥物。與其他第一代藥物相比,阿伐那非具有更好的亞型選擇性,且產生副作用的機率較低。然而目前尚無第五型磷酸二酯酶與阿伐那非的複合體結構,所以尚無法從結構的角度上得知阿伐那非相較於其他的抑制劑有更好亞型選擇性的原因。為了得知阿伐那非作用的結構機轉,並獲得可提供下一代藥物設計的結構資訊,我們將第五型磷酸二酯酶與阿伐那非進行共結晶,並成功獲得解析度達1.92 Å的複合體晶體結構。基於所解出的結構資訊,我們得知了阿伐那非的結合模式,並搭配磷酸二酯酶亞型間的序列比對結果,推論不同亞型之間數個位置的胺基酸序列差異是決定阿伐那非有較好亞型選擇性的關鍵。除此之外,藥物結構中氯原子與酵素活性中心之α螺旋主鏈氧原子形成的鹵素鍵,亦提供了一個新的藥物設計概念,我們認為鹵素鍵的形成除了可增強藥物的結合力,並可提高藥物的選擇性。而這些資訊,應有助於設計出具有更高選擇性以及更低副作用新一代抑制劑。 | zh_TW |
dc.description.abstract | Cyclic nucleotide phosphodiesterases (PDEs) constitute a large enzyme superfamily that, depending on sequence variation and differences in substrate specificity, is further classified into 11 subfamilies. PDEs are responsible for the breakdown of two important secondary messengers - cAMP and cGMP. Because these two cyclic nucleotides relay the extracellular signals and directly control the activities of various signal transduction pathways to induce physiological changes, such as cell proliferation, differentiation, anti-apoptosis and apoptosis, thus their cellular concentrations are tightly regulated. And the catalytic activities of PDEs play an important role in controlling cAMP and cGMP cellular concentrations. For this reason, PDEs are valid targets for drug development, whose inhibition may alleviate several symptoms by increasing cAMP or cGMP levels. Among numerous PDEs inhibitors, the development of PDE5-specific inhibitors represent one of the most successful cases in medicinal chemistry. The sildenafil, vardenafil, tadalafil, and avanafil are four PDE5 inhibitors in wide clinical use for treating pulmonary arterial hypertension, cardiovascular disease, benign prostatic hyperplasia, and erectile dysfunction. Among them, avanafil is the only FDA-approved second generation inhibitor which exhibits improved PDE isoform selectivity and reduced adverse effects compared to the first generation drugs. However, the molecular basis underlying avanafil’s better isoform selectivity has remained elusive due to the lack of PDE5-avanafil complex structure. To this end, we co-crystallized human PDE5 and avanafil and successfully determined the complex structure at 1.92 Å. Analysis of protein-drug interactions revealed structural basis of avanafil’s superior isoform selectivity. Moreover, a halogen bonding was observed between avanafil and a backbone carbonyl oxygen of an adjacent α-helix, whose contribution to inhibitory potency illustrates the feasibility of exploiting α-helix backbone in structure-based drug design. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T05:00:55Z (GMT). No. of bitstreams: 1 U0001-1808202023010400.pdf: 17295623 bytes, checksum: 701f8c10d9e7de0cbcf7dfb44d67b50e (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 謝誌 ................................................................................................................................................................................... II 論文摘要 .......................................................................................................................................................................... IV ABSTRACT ...................................................................................................................................................................... V INTRODUCTION .............................................................................................................................................................. 1 FUNCTIONS OF 3’, 5’-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE .................................................................................. 1 THE PROPERTIES AND CLASSIFICATION OF PDE ISOFORMS .............................................................................................. 2 DIFFERENT SUBSTRATE PREFERENCES AND TISSUE DISTRIBUTIONS OF PDE ISOFORMS ARE KEY PROPERTIES ASSOCIATED WITH DISEASE TREATMENTS ............................................................................................................................................ 3 PDE5 CLINICAL USED INHIBITORS .................................................................................................................................. 7 HALOGEN BONDING ........................................................................................................................................................ 8 SPECIFIC AIM OF THIS STUDY .......................................................................................................................................... 9 METHODS AND MATERIALS ...................................................................................................................................... 11 PROTEIN EXPRESSION, PURIFICATION, AND MUTAGENESIS ............................................................................................... 11 CRYSTALLIZATION AND DATA COLLECTION ...................................................................................................................... 11 STRUCTURE DETERMINATION ......................................................................................................................................... 12 STRUCTURAL MODELING OF AVANAFIL-BOUND PDE ISOFORMS ...................................................................................... 13 ENZYMATIC ASSAY .......................................................................................................................................................... 13 RESULTS AND DISCUSSION ....................................................................................................................................... 15 X-RAY CRYSTALLOGRAPHY AND OVERALL STRUCTURE OF PDE5-AVANAFIL COMPLEX ...................................................... 15 INTERACTIONS BETWEEN PDE5 AND AVANAFIL ............................................................................................................... 17 MOLECULAR CODE FOR TARGETING MAIN CHAIN CARBONYL GROUP OF AN Α-HELIX BY HALOGEN. ................................. 21 STRUCTURAL BASIS OF IMPROVED ISOFORM SELECTIVITY OF AVANAFIL. .......................................................................... 24 i) The branched or aromatic amino acids surround to class I halogen bonding holes. .......................................... 25 ii) Lost interaction in the other PDE isoforms. ....................................................................................................... 26 iii) Weaker interactions with avanafil than PDE5 in other PDE isoforms. ............................................................. 28 THE ANALYSIS OF AVANAFIL SELECTIVITY IMPROVEMENT COMPARED TO SILDENAFIL, VARDENAFIL, AND TADALAFIL. ........... 32 SUMMARY ...................................................................................................................................................................... 33 FIGURES ......................................................................................................................................................................... 35 FIGURE 1. THE CAMP, CGMP, AND PDES INVOLVE IN CELL SIGNALING AND REGULATION. .......................................... 35 FIGURE 2. THE HYDROLYSIS ACTIVITY OF PDES. .......................................................................................................... 36 FIGURE 3. THE GENERAL STRUCTURE OF PDES. ........................................................................................................... 37 FIGURE 4. THE GENERAL STRUCTURE OF PDE ISOFORMS CATALYTIC DOMAIN. ............................................................. 38 FIGURE 5. THE TWO METAL IONS PLAY AN IMPORTANT ROLE IN CYCLIC NUCLEOTIDE PHOSPHATE GROUP HYDROLYSIS. 39 viii FIGURE 6. THE TISSUE DISTRIBUTION PATTERNS OF PDE ISOFORMS. ............................................................................. 40 FIGURE 7. THE NO-CGMP PATHWAY. ............................................................................................................................ 41 FIGURE 8. THE XANTHINE DERIVATES AND INHIBITION MECHANISM ............................................................................. 42 FIGURE 9. THE STRUCTURES OF FOUR GENERAL PDE5 INHIBITORS............................................................................... 43 FIGURE 10. THE Σ-HOLE MODEL. ................................................................................................................................... 44 FIGURE 11. THE ANGLES AND BOND DISTANCES OF HALOGEN BONDING........................................................................ 45 FIGURE 12. THE RESULTS OF GEL-FILTRATION CHROMATOGRAPHY AND SDS-PAGE OF PURIFIED PDE5. ..................... 46 FIGURE 13. THE PDE5-AVANAFIL COMPLEX CRYSTAL .................................................................................................. 47 FIGURE 14. STRUCTURE OF THE PDE5 CATALYTIC CORE IN COMPLEX WITH AVANAFIL. ................................................. 48 FIGURE 15. STEREO DIAGRAM SHOWING THE OVERALL STRUCTURE OF THE PDE5-AVANAFIL COMPLEX. ..................... 49 FIGURE 16. ELECTRON DENSITY FOR THE BIMETAL CENTER OBSERVED AT THE ACTIVE SITE OF PDE5. ......................... 50 FIGURE 17. COMPARING THE BINDING MODES AND INTERACTING RESIDUES OF SILDENAFIL, VARDENAFIL, TADALAFIL AND AVANAFIL WITH RESPECT TO GMP. ........................................................................................................................ 51 FIGURE 18. INTERACTIONS BETWEEN PDE5 AND AVANAFIL. ......................................................................................... 52 FIGURE 19. INVOLVEMENT OF THE “HYDROPHOBIC CLAMP” AND “GLUTAMINE SWITCH” OF PDE5 IN AVANAFILBINDING. ....................................................................................................................................................................... 53 FIGURE 20. A BACKBONE CARBONYL OXYGEN FROM HELIX Α14 FORMS A HALOGEN BONDING WITH AVANAFIL (PDB CODE 6L6E). ................................................................................................................................................................. 54 FIGURE 21. SCHEMATIC DIAGRAMS SHOWING THE GUIDELINES FOR TARGETING Α-HELIX BACKBONE BY HALOGEN BONDING. ...................................................................................................................................................................... 55 FIGURE 22. THE AMINO ACIDS SURROUND THE PDE5 CL BINDING HOLE IN PDE1, PDE2, PDE3, PDE7, PDE9, AND PDE10, AND PDE11. .................................................................................................................................................... 56 FIGURE 23. THE CONFORMATIONAL CHANGES OF AMINO ACIDS AT THE SAME SITE AS PDE5 I729 IN PDE1, PDE3, PDE4, PDE7, PDE8, AND PDE9. ................................................................................................................................. 57 FIGURE 24. THE AMINO ACIDS AT THE PDE5 I729 SITE IN PDE6 AND PDE11. .............................................................. 58 FIGURE 25. THE AMINO ACIDS IN PDE2, PDE7, PDE8, PDE9, PDE10, AND PDE11 RELATED TO PDE5 Q775. ............ 59 FIGURE 26. THE POLAR AMINO ACIDS SUBSTITUTE TO NONPOLAR AMINO ACIDS RELATED TO PDE5 A767 IN PDE1, PDE2, PDE4, PDE7, PDE8, PDE9, AND PDE10. ......................................................................................................... 60 FIGURE 27. THE AMINO ACIDS IN PDE1 AND PDE3 AT THE LOCATION RELATED TO PDE5 Q775. .................................. 61 FIGURE 28. THE INTERACTIONS OF AVANAFIL CONTACTED WITH PDE5 I813 AND PDE9 K449. .................................... 62 FIGURE 29. THE AMINO ACIDS RELATED TO PDE5 M816 IN PDE1, PDE4, PDE8, PDE9, AND PDE10. ........................ 63 FIGURE 30. THE AMINO ACID RELATED TO PDE5 F820 IN PDE11. ................................................................................ 64 FIGURE 31. SCHEMATIC DIAGRAMS SHOWING THE MOLECULAR BASIS OF AVANAFIL’S IMPROVED SAFETY. ................... 65 TABLES ........................................................................................................................................................................... 66 TABLE 1. THE SUBSTRATE SPECIFICITY, KM, VMAX OF PDE ISOFORMS. ............................................................................ 66 TABLE 2. THE TISSUE DISTRIBUTION, INHIBITORS AND CLINICAL APPLICATIONS OF PDE ISOFORMS .............................. 67 TABLE 3. THE PHARMACOKINETICS OF CURRENTLY PDE5 INHIBITORS IN CLINICAL USED. ........................................... 68 TABLE 4. INCIDENCE OF ADVERSE EFFECTS OF PDE5 INHIBITORS (%) .......................................................................... 69 ix TABLE 5. DATA COLLECTION AND REFINEMENT STATISTICS. ........................................................................................ 70 TABLE 6. THE RESULTS OF PDE5 CATALYTIC ASSAYS (STANDARD CURVE) .................................................................... 71 TABLE 7. THE RESULTS OF PDE5 CATALYTIC (CHANGE AMINO ACIDS AT THE HALOGEN BINDING HOLE). ...................... 72 TABLE 8. THE RESULTS OF PDE5 CATALYTIC (MUTANTS AT THE POTENTIAL INFLUENT SITES).. ..................................... 73 TABLE 9. RESIDUES INVOLVED IN PDE5-INHIBITORS INTERACTIONS. ........................................................................... 74 TABLE 10. SEQUENCE VARIATION OF AVANAFIL-INTERACTING RESIDUES AMONG PDES................................................ 75 TABLE 11. PDE SELECTIVITY OF THE THREE FIRST GENERATION PDE5 INHIBITOR AND THE SECOND GENERATION INHIBITOR -AVANAFIL. ................................................................................................................................................... 76 REFERENCES ................................................................................................................................................................. 77 | |
dc.language.iso | en | |
dc.title | 人類第五型磷酸二酯酶與其抑制藥物阿伐那非之複合體結構揭示其亞型選擇性機制以及針對α螺旋主鍊氧原子之鹵素鍵設計方針 | zh_TW |
dc.title | Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting α-Helix Backbone Oxygen by Halogen Bonding | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 林敬哲(Jing-Jer Lin),何孟樵 (Meng-Chiao Ho),李宗璘(Tsung-Lin Li),陳基旺(Ji-Wang Chern),徐駿森(Chun-Hua Hsu) | |
dc.subject.keyword | 人類第五型磷酸二酯酶,阿伐那非,鹵素鍵,主鏈氧原子,α螺旋, | zh_TW |
dc.subject.keyword | human Phosphodiesterase 5A1,avanafil,halogen bonding,backbone carbonyl oxygen,α-helix, | en |
dc.relation.page | 82 | |
dc.identifier.doi | 10.6342/NTU202004042 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1808202023010400.pdf 目前未授權公開取用 | 16.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。